레노보 RX(RNXT)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.69 (-2.31%), 시가총액 $36.98M.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
레노보 RX의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
레노보 RX의 현재 주가는 $1.69 (-2.31%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
레노보 RX의 시가총액은 약 $36.98M입니다.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.